| 标题 |
A randomized phase 2 ASPEN-Breast clinical trial will evaluate evorpacept with HERCEPTIN(trastuzumab) and single-agent chemotherapy in patients with HER2-positive metastatic breast cancer after prior treatment with ENHERTU
一项随机2期ASPEN-Breast临床试验将评估evorpacept与赫赛汀(曲妥珠单抗)和单药化疗在既往接受ENHERTU治疗后的HER2阳性转移性乳腺癌患者中的应用
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 其它 | ALX oncology media release |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)